Norditropin coverage ending for commercial members effective Jan. 1, 2024

Due to severe shortages, Norditropin® coverage will end for our commercial group and individual members on Dec. 31, 2023. This includes both new-start and existing prescriptions.

Norditropin will remain on the Medicare formulary, with prior authorization requirements, through 2024.

Effective Jan. 1, 2024, Omnitrope®, an HGH drug, will be added to formulary as a tier 4 drug with prior authorization requirements.

How will this impact you?

Beginning Jan. 1, 2024, you’ll need to write impacted members a new prescription for either Genotropin or Omnitrope and send it to an in-network specialty pharmacy.

To assist you with this transition, prior authorizations for Genotropin and Omnitrope have been added for members with current authorizations on file for Norditropin.

For new starts on Genotropin or Omnitrope, prior authorization is required.

To avoid interruptions in their care, members have been encouraged to speak with their providers about whether transitioning to Genotropin or Omnitrope is right for them.

Thank you for partnering with us in our commitment to providing the best possible treatment options for your patients, our members.